Charles River Laboratories Intl. Inc vs NRG Energy Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.95 (market cap $14.23B), while NRG Energy Inc trades at $107.42 (market cap $22.35B). The key difference: NRG Energy Inc is the larger of the two by market cap, and NRG Energy Inc pays a 1.79% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and NRG Energy Inc for 63 Days on average.
| CRL | NRG | |
|---|---|---|
Market Cap | $14.23B | $22.35B |
Volume | 1,176,885 | 5,011,942 |
Sector | Health | Utilities |
52-Week High | $310.77 | $184.03 |
52-Week Low | $149.93 | $95.23 |
Typical Hold Time | 33 Days | 63 Days |
Enterprise Value | $17.06B | $46.30B |
Dividend Yield | — | 1.79% |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
NRG Energy trades at $107.24, down 1.26% on the day, with a bullish technical signal supported by moving averages. The company shows strong profitability with 26.77% ROE and 2.56% net margin, though recent Q1 and Q2 2026 earnings missed expectations. Revenue growth remains positive, reaching $30.71B in 2025, while valuation metrics show a P/E of 27.69 and P/S of 0.65. Recent developments include a 1.2 GW Texas data center power project and potential acquisition of a West Virginia coal plant.
Outlook remains positive with analyst consensus strongly bullish (70% buy ratings) and a $202.90 price target suggesting significant upside. Key risks include rising debt levels (56.42% debt-to-asset ratio) and execution challenges on major capital projects. The company's dual retail/generation model provides stability, but investors should monitor earnings delivery against high expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →